ImmunityBio (IBRX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for June 18, 2025, at 9:30 A.M. Pacific Time, with virtual attendance available.
Shareholders are encouraged to review proxy materials and vote by June 17, 2025.
Voting matters and shareholder proposals
Election of eight directors is on the agenda, with board recommendations provided for each nominee.
Proposal to approve the 2025 Equity Incentive Plan.
Proposal to ratify Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Proxies may vote on other business that arises at the meeting.
Board of directors and corporate governance
Director nominees include Patrick Soon-Shiong, Cheryl L. Cohen, Richard Adcock, Michael D. Blaszyk, Wesley Clark, Linda Maxwell, Christobel Selecky, and Barry J. Simon.
Latest events from ImmunityBio
- Q1 2026 revenue surged 168% to $44.2M, but net loss deepened to $632.8M on non-cash charges.IBRX
Q1 20267 May 2026 - Director elections and auditor ratification headline the June 2026 virtual shareholder meeting.IBRX
Proxy filing30 Apr 2026 - Record revenue growth, global approvals, and robust governance highlight this year's proxy.IBRX
Proxy filing30 Apr 2026 - 700% revenue growth to $113M, global expansion, and net loss narrowed to $351M.IBRX
Q4 202530 Apr 2026 - Global immunotherapy expansion accelerates with durable clinical results and new market launches.IBRX
The Citizens Life Sciences Conference 202628 Apr 2026 - ANKTIVA drives global immunotherapy growth with strong efficacy, approvals, and financial momentum.IBRX
Investor presentation11 Mar 2026 - FDA approval, robust NMIBC efficacy, and global expansion drive strong growth.IBRX
Investor Day 20253 Feb 2026 - Stockholders will vote on director elections, a new equity plan, and auditor ratification.IBRX
Proxy Filing1 Dec 2025 - Strong ANKTIVA uptake, global expansion, and pivotal trial progress drive near-term milestones.IBRX
Jefferies London Healthcare Conference 202519 Nov 2025